RPL34

Large ribosomal subunit protein eL34 · P49207 · RPL34 on Sugi Atlas →

3,642 patent compounds predicted against RPL34, 1,902 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL34 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Tumor Gene Expression in Women With Ovarian Cancer	PHASE4	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
RibOSE - Glucose and Resistance Exercise Training	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Effects of Acute Energy Deficit and Aerobic Exercise on Muscle Quality	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPL34 binder may also engage these)

Protein	Name	Similarity
G1TXG5	—	1.000	G1TXG5 →
Q9D1R9	—	0.996	Q9D1R9 →
Q29223	—	0.994	Q29223 →
Q90YT5	—	0.966	Q90YT5 →
Q7ZWJ7	—	0.963	Q7ZWJ7 →
P40590	—	0.940	P40590 →
P42794	—	0.919	P42794 →
G1SZ47	—	0.919	G1SZ47 →
P62268	—	0.919	P62268 →
A2YDY2	—	0.918	A2YDY2 →
Q6SA96	—	0.917	Q6SA96 →
P62267	—	0.916	P62267 →
Q3T199	—	0.916	Q3T199 →
P62250	—	0.915	P62250 →
Q0DK10	—	0.914	Q0DK10 →
P62298	—	0.914	P62298 →
RPS23	Small ribosomal subunit protein uS12	0.914	landscape →
RPS16	Small ribosomal subunit protein uS9	0.912	landscape →
P14131	—	0.912	P14131 →
Q29201	—	0.912	Q29201 →
G1SGX4	—	0.912	G1SGX4 →
Q3T0X6	—	0.912	Q3T0X6 →
Q90YQ1	—	0.912	Q90YQ1 →
Q4R7Y2	—	0.912	Q4R7Y2 →
Q2TBW8	—	0.911	Q2TBW8 →
P86048	—	0.911	P86048 →
Q86FP7	—	0.911	Q86FP7 →
Q5R931	—	0.909	Q5R931 →
Q9XSI3	—	0.908	Q9XSI3 →
P46287	—	0.908	P46287 →